NEUROONE MEDICAL TECHNOLOGIE (NMTC) Institutional Buying Activity
Institutional investors tracked by InsiderSet increased exposure to NEUROONE MEDICAL TECHNOLOGIE (NMTC) during the quarter ended March 31, 2026 through a combination of new purchases and expanded existing positions disclosed in SEC Form 13F filings.
Several hedge funds and long-term asset managers reported increases in NMTC exposure during the latest reporting period based on SEC Form 13F filings.
Institutional buying activity can provide insight into investor conviction, sector allocation trends, and smart money positioning toward NEUROONE MEDICAL TECHNOLOGIE (NMTC). InsiderSet tracks quarterly accumulation trends, new institutional positions, ownership increases, and estimated performance of newly disclosed holdings using SEC filing data and recent market prices.
No data available.
Frequently asked questions about NMTC activity
Which institutional owners are buying NMTC?
Institutional owners buying NMTC include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.
What does "buy" mean in NMTC activity?
"Buy" means an investor increased their reported position in NMTC compared to the prior reporting period. This reflects growing exposure to NEUROONE MEDICAL TECHNOLOGIE (NMTC) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).
Is institutional interest in NMTC increasing?
Institutional interest in NMTC can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.